medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2014, Number 610

<< Back Next >>

Rev Med Cos Cen 2014; 71 (610)

Actualización sobre el uso de Hipoglicemiantes orales para el tratamiento farmacológico en diabetes mellitus gestacional

García-Herrera E

Language: Spanish
References: 27
Page: 225-229
PDF size: 208.05 Kb.


ABSTRACT

Clinical guidelines regarding gestational diabetes aim only to the use of insulin as traditional therapy; oral hypolycemic agents such as metformin or glyburide are not yet approved by official guidelines, however, many authors consider the use of oral hypoglicemic agents as first line treatment for patients who fail to maintain hipoglicemia with diet and exercise only. There is no consistent evidence of risk for developing adverse reactions both to the fetus or to the mother with the use of these medications compared to the use of insulin, even so, there is an arising number of reports, observational studies, randomized and comparative trials, which might lead in the future to new guidelines of treatment, yet there is still controversy regarding the use of these agents as treatment option for gestational diabetes.


REFERENCES

  1. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004; 27 (suppl 1): SS 88-S90

  2. Cheung NW. The management of gestational diabetes. Vasc Health Risk Manag 2009 5, 153–164.

  3. Coetzee E, Jackson WPU. Oral hypoglycaemics in the first trimester and fetal outcomes. S Afr Med J 1984

  4. Coustan DR. Pharmacological management of gestational diabetes: An overview. Diabetes Care 2007; 30:S206-S208.

  5. Feig DS, Briggs GG & Koren G. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? Annals of Pharmacotherapy 2007 41 1174– 1180.

  6. Galerneau F, Inzucchi SE. Diabetes mellitus in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 907–33.

  7. Glueck CJ, Goldenberg N, Streicher P and Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002 3,1557–1568.

  8. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse GARCIA: Uso de Hipoglicemiante s Orale s en Dia bete s Mellit us Gestacional 229 pregnancy outcomes. N Engl J Med 2008 358; 19

  9. Holt RI, Clarke P, Parry EC, Coleman MAG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes Obes Metab. 2008; 10:906–911.

  10. Homko CJ, Reece EA. Insulins and oral hypoglycemic agents in pregnancy. The Journal of Maternal- Fetal and Neonatal Medicine. 2006; 19:679–686

  11. Kjos, SL, et al. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitus in the first two months postpartum. Am. J. Obstet. Gynecol. 1990. 163:93-98.

  12. Langer, O, Conway, DL, Berkus, MD, Xenakis, EM, Gonzales, O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N. Engl. J. Med. 2000. 343:1134-1138.

  13. Langer O, Yogev Y, Xenakis EM, et al. Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005; 192:134- 139.

  14. Langer O. Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol Metab Clin N Am. 2006; 35:53-78.

  15. Langer O. Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus. Obstet Gynecol Clin North Am 2007; 34:255-274.

  16. Langer O. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2002; 11:218–25

  17. Lee-Parritz A. Contemporary management of gestational diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2011, 18(6):395-400.

  18. Maymone AC, Baillargeon JP, Menard J and Ardilouze JL. Oral hypoglycemic agents for gestational diabetes mellitus? Expert Opin Drug Saf 2011 10(2):227-238.

  19. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol. 2009;113:193–205.

  20. Notelowitz M. Sulphonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971; 45: 226-9.

  21. Paglia MJ, Coustan DR. The use of oral antidiabetic medications in gestational diabetes mellitus. Curr Diab Rep 2009. Aug;9(4):287-290.

  22. Pollex EK, Feig DS, Koren G. Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer. J Matern Fetal Neonatal Med. 2010 Mar; 23(3):224-8

  23. Ramos GA, Jacobson GF, Kirby RS, et al. Comparison of glyburide and insulin for the management of gestationial diabetes with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol. 2007; 27:262–267.

  24. Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001; 94:435

  25. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358:2003-2015.

  26. Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012 Jan 10; 40(3):225-8.

  27. Tran ND. Oral hypoglycemic agents in pregnancy. Obst Gynecol Surv 2004; 59(6):456-63.




2020     |     www.medigraphic.com